Doctors prescribe Evenity (romosozumab-aqqg) to treat postmenopausal osteoporosis. The drug falls under Medicare Part B coverage because a healthcare professional needs to administer it. You may get ...

The U.S. Food and Drug Administration has approved a drug treatment specifically for postmenopausal women with a high risk of breaking bones. Doses are taken in two back-to-back injections ...

(Reuters) - Amgen Inc on Monday set the U.S. list price for its new Evenity osteoporosis drug at $1,825 a month, or $21,900 for a full 12-month course of injections. The U.S. Food and Drug ...

Amgen recently had two big wins. First, after years of wrangling with the FDA, they finally won approval for their innovative osteoporosis drug, Evenity. Second, Amgen launched Evenity at a price ...

The Food and Drug Administration (FDA) has approved Evenity (romosozumab-aqqg; Amgen) injection for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a ...

The European Medicines Agency has accepted UCB and Amgen’s submission seeking approval for use of bone-boosting drug Evenity in post-menopausal women and in men at increased risk of fracture. The ...

THOUSAND OAKS, Calif., April 15, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that EVENITY™ (romosozumab-aqqg) is now available for shipment to wholesalers in the U.S. EVENITY was ...

The US Food and Drug Administration has approved a new treatment for osteoporosis in postmenopausal women who are at high risk of bone fractures. The FDA announced Tuesday that the drug, called ...

Doctors prescribe Evenity (romosozumab-aqqg) for treating postmenopausal osteoporosis. The drug falls under Medicare Part B coverage because a healthcare professional must administer the injection. As ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: An Amgen sign is seen at the company's office in South San Francisco, California in this October 21, 2013 file photo.